By month two, something shifted
The HbA1c reductions demonstrated in the SURPASS trials (up to 2.4% reduction) were achieved with injectable administration under controlled conditions
Dry or hard stool is often difficult to pass and can be a direct result of the slowed gastric emptying associated with GLP-1 receptor agonists like semaglutide
Molecular Medicine Reports , 2014
Global NASH Council, American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, European Liver Patients' Association - ELPA, Global Liver Institute, Priti Chawla, Obesity Matters, American Diabetes Association Fatty Liver Alliances Post GLP-1 receptor agonists (GLP-1RAs) show promise in managing metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing hepatic steatosis, resolving MASH, and mitigating fibrosis progression
These are similar to other GLP-1 medications, but the intensity and severity of these side effects are slightly higher with retatrutide